ORPHA:221
Dermatomyositis
Also known as: Adult dermatomyositis
Publications
30,844
Trials
123
Interventional, condition-specific
Researchers
1,138
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare inflammatory (IIM) characterized by evocative skin lesions, muscle involvement with symmetrical proximal muscle weakness, and specific histological features. The clinical subtypes are defined by the presence of myositis-specific antibodies (anti-Mi2, anti-NXP2, anti-TIF1-γ, anti-MDA5, or anti-SAE antibodies) and are associated with specific clinical phenotypes and prognosis.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016367
- MeSH:D003882
- UMLS:C0011633
- NCIT:C26744
Additional Mondo synonyms (3)
DM · dermatomyositis · dermatopolymyositis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
30,844 matched papers (16,058 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
123 matched on ClinicalTrials.gov (36 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
30,844
30,844 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
30,844 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
16,058 in the last 10 years · low confidence
Phrase hits: 30,844 · MeSH hits: 0
Who's working on it?
1,138
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Xu X6 papers · 2026
Department of Rheumatology Immunology & Allergy, The Children's Hospital, National Clinical Research Center for Child Health, Zhejiang University School of Medicine, Binsheng Rd 3333, Binjiang District, Hangzhou, 310052, P.R. China. xuxuefeng@zju.edu.cn.
Papers in Europe PMC - 02Wang J5 papers · 2026
Department of Neurology, The First Hospital of Shanxi Medical University, 030001 Taiyuan, Shanxi, China.
Papers in Europe PMC - 03Yang J5 papers · 2026
Department of Dermatology, Zhongshan Hospital of Fudan University, Shanghai, China.
Papers in Europe PMC - 04Liu J4 papers · 2026
Department of Oncology, Yuhuangding Hospital, Affiliated with Medical College of Qingdao University, Yantai, Shandong, China.
Papers in Europe PMC - 05Nigro A4 papers · 2026
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York City, NY.
Papers in Europe PMC - 06Rider LG4 papers · 2026
L.G. Rider, MD, Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, Maryland, USA.
Papers in Europe PMC - 07Allenbach Y3 papers · 2026
Centre National de Référence des Myopathies Inflammatoires, Département de Médecine Interne et Immunologie Clinique, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris.
Papers in Europe PMC - 08Benveniste O3 papers · 2026
Centre National de Référence des Myopathies Inflammatoires, Département de Médecine Interne et Immunologie Clinique, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris.
Papers in Europe PMC - 09Chen Z3 papers · 2026
Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Papers in Europe PMC - 10Christopher-Stine L3 papers · 2026
Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
123
interventional trials for this specific condition
123 interventional trials matched this specific condition name; 36 currently recruiting in our sample.
Data as of 27 July 2026
123 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 98.7th percentile).
low confidence · 98.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
123 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06686524·RECRUITING·Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)
Conditions: Dermatomyositis, Juvenile · Dermatomyositis·Matched via name phrase
- NCT07349667·NOT YET RECRUITING·Hypnotherapy for Needle-related Procedural Pain and Anxiety Management in a Pediatric Setting
Conditions: Arthritis, Juvenile · Arthritis, Juvenile Idiopathic · Lupus Erythematosus, Systemic · Dermatomyositis, Juvenile·Matched via name phrase
- NCT06371417·RECRUITING·Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Conditions: Antiphospholipid Syndrome (APS) · Bullous Pemphigoid (BP) · Behçet's Syndrome (BS) · Dermatomyositis (DM)·Matched via name phrase
- NCT03582800·RECRUITING·Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study
Conditions: Systemic Sclerosis · Dermatomyositis · iPPSD2·Matched via name phrase
- NCT05495321·ENROLLING BY INVITATION·Interleukin-2 on Active Dermatomyositis
Conditions: Dermatomyositis·Matched via name phrase
- NCT07160205·RECRUITING·Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)
Conditions: Idiopathic Inflammatory Myositis (IIM) · DERMATOMYOSITIS OR POLYMYOSITIS·Matched via name phrase
- NCT07184450·RECRUITING·Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
Conditions: Juvenile Dermatomyositis (JDM) · Polyarticular Juvenile Idiopathic Arthritis · Systemic Sclerosis (SSc) · Primary Sjogren's Syndrome·Matched via name phrase
- NCT04972760·RECRUITING·Baricitinib in Patients With Relapsing or naïve Dermatomyositis
Conditions: Dermatomyositis·Matched via name phrase
- NCT06857240·RECRUITING·Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
Conditions: Dermatomyositis·Matched via name phrase
- NCT06568783·NOT YET RECRUITING·Evaluation of Patients With Refractory Dermatomyositis Using [18F] FAPI-74 PET/MRI Imaging
Conditions: Refractory Dermatomyostitis·Matched via name phrase
- NCT05895786·RECRUITING·A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
Conditions: Myositis·Matched via name phrase
- NCT05979441·ENROLLING BY INVITATION·A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
Conditions: Myositis · Active Idiopathic Inflammatory Myopathy · Dermatomyositis · Polymyositis·Matched via name phrase
- NCT06154252·RECRUITING·RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Conditions: Idiopathic Inflammatory Myopathy · Dermatomyositis · Anti-Synthetase Syndrome · Immune-Mediated Necrotizing Myopathy·Matched via name phrase
- NCT06685042·RECRUITING·Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases
Conditions: Lupus Erythematosus, Systemic · System; Sclerosis · ANCA Associated Vasculitis · Dermatomyositis·Matched via name phrase
- NCT06298019·RECRUITING·Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis
Conditions: Dermatomyositis·Matched via name phrase
Observational and natural-history studies
40 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07265999·RECRUITING·Severity Factors of Dermatomyositis in the Caribbean Population - DM-ANTILLES
Conditions: Dermatomyositis·Matched via name phrase
- NCT06462768·RECRUITING·Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis
Conditions: Systemic Sclerosis · Other Connective Tissue Disease · Systemic Lupus Erythematosus · Dermatomyositis·Matched via name phrase
- NCT06004817·RECRUITING·Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis
Conditions: Dermatomyositis·Matched via name phrase
- NCT02945345·RECRUITING·Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
Conditions: Dermatomyositis·Matched via name phrase
- NCT07374107·RECRUITING·MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
Conditions: IBM · IIM · Myositis · Inflammatory Myopathy·Matched via name phrase
- NCT06339957·RECRUITING·Rheumatology Diet Study
Conditions: Diet Habit · Rheumatologic Disease · Autoimmune Diseases · Rheumatoid Arthritis·Matched via name phrase
- NCT00017914·RECRUITING·Adult and Juvenile Myositis
Conditions: Dermatomyositis · Polymyositis · Inclusion Body Myositis·Matched via name phrase
- NCT00059748·RECRUITING·Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile Dermatomyositis
Conditions: Autoinflammatory Disease · Juvenile Dermatomyositis·Matched via name phrase
- NCT06203249·RECRUITING·Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
Conditions: Microbiome · Immune Function · Anti-MDA5 Antibody Positive Dermatomyositis·Matched via name phrase
- NCT01276470·RECRUITING·Environmental Risk Factors for the Anti-synthetase Syndrome
Conditions: Myositis · Dermatomyositis · Polymyositis · Juvenile Dermatomyositis·Matched via name phrase
- NCT04402086·RECRUITING·Rheumatology Patient Registry and Biorepository
Conditions: Rheumatic Diseases · Adult Onset Still Disease · Ankylosing Spondylitis · Psoriatic Arthritis·Matched via name phrase
- NCT07403188·RECRUITING·A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Conditions: Refractory Lupus Nephritis · Myasthaenia Gravis · Stiff Person Syndrome · Rheumatoid Arthritis (RA)·Matched via name phrase
- NCT07345949·RECRUITING·Panniculitis in Dermatomyositis
Conditions: Panniculitis · Dermatomyositis·Matched via name phrase
- NCT06599411·RECRUITING·Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
Conditions: Atopic Dermatitis · Psoriasis · Hidradenitis Suppurativa · Lichen Planus·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Dermatomyositis" OR "Adult dermatomyositis" OR "dermatopolymyositis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Dermatomyositis" OR "Adult dermatomyositis" OR "dermatopolymyositis"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 123 interventional · 40 observational · 1 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: DM
Confidence reasoning
- Preferred label is short or not clearly distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T12:57:27.807Z
